Pilot Data Supporting Omega-3 Fatty Acids Supplementation in Medicated Children with Attention-Deficit/Hyperactivity Disorder and Deficits in Emotional Self-Regulation

TY - JOUR

T1 - Pilot Data Supporting Omega-3 Fatty Acids Supplementation in Medicated Children with Attention-Deficit/Hyperactivity Disorder and Deficits in Emotional Self-Regulation

AU - Wilens, Timothy E.

AU - Carrellas, Nicholas W.

AU - Zulauf, Courtney

AU - Yule, Amy M.

AU - Uchida, Mai

AU - Spencer, Andrea

AU - Biederman, Joseph

N1 - Funding Information: T.E.W.: T.E.W. receives or has received grant support from the following sources: NIH (NIDA). He is or has been a consultant for Alcobra, Neurovance/Otsuka, and Ironshore. T.E.W. receives grant funding from NIH (NIDA) and has published a book: Straight Talk About Psychiatric Medications for Kids (Guilford Press); and co/edited books ADHD in Adults and Children (Cambridge University Press), Massachusetts General Hospital Comprehensive Clinical Psychiatry (Elsevier), and Massachusetts General Hospital Psychopharmacology and Neurotherapeutics (Elsevier). T.E.W. is co/owner of a copyrighted diagnostic questionnaire (Before School Functioning Questionnaire). He also has a licensing agreement with Ironshore (BSFQ Questionnaire). T.E.W. is Chief, Division of Child and Adolescent Psychiatry and (Co) Director of the Center for Addiction Medicine at Massachusetts General Hospital. He serves as a clinical consultant to the U.S. National Football League (ERM Associates), U.S. Minor/Major League Baseball; Phoenix House and Bay Cove Human Services. A.M.Y. received grant support from the American Academy of Child and Adolescent Psychiatry Pilot Research Award for Junior Faculty supported by Lilly USA, LLC in 2012. She received grant support from the Massachusetts General Hospital Louis V. Gerstner III Research Scholar Award from 2014 to 2016. A.M.Y. is currently receiving funding through the American Academy of Child and Adolescent Psychiatry Physician Scientist Program in Substance Abuse K12DA000357-17. She is a consultant to Phoenix House (clinical service). In 2016, A.S. received honoraria for tuition-funded CME courses and received research support from Sunovion. J.B. is currently receiving research support from the following sources: The Department of Defense, Food & Drug Administration, Lundbeck, Merck, Neurocentria, Inc., PamLab, Pfizer, Shire Pharmaceuticals, Inc., SPRITES, Sunovion, and NIH. J.B.’s program has received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Ingenix, Prophase, Shire, Bracket Global, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH. In 2016, J.B. received honoraria from the MGH Psychiatry Academy for tuition-funded CME courses, and from Avekshan, Alcobra, and AACAP. He has a U.S. Patent Application pending (Provisional Number #61/233,686) through MGH corporate licensing, on a method to prevent stimulant abuse. In 2015, J.B. received honoraria from the MGH Psychiatry Academy for tuition-funded CME courses, and from Avekshan. He received research support from Ironshore, Mag-ceutics, Inc., and Vaya Pharma/Enzymotec. In 2014, J.B. received honoraria from the MGH Psychiatry Academy for tuition-funded CME courses. He received research support from AACAP, Alco-bra, Forest Research Institute, and Shire Pharmaceuticals, Inc. In 2013, J.B. received an honorarium from the MGH Psychiatry Academy for a tuition-funded CME course. He received research support from APSARD, ElMindA, McNeil, and Shire. In previous years, J.B. received research support, consultation fees, or speaker’s fees for/from the following additional sources: Abbott, Alza, AstraZeneca, Boston University, Bristol Myers Squibb, Cambridge University Press, Celltech, Cephalon, The Children’s Hospital of Southwest Florida/Lee Memorial Health System, Cipher Pharmaceuticals, Inc., Eli Lilly and Co., Esai, Fundacion Areces (Spain), Forest, Fundación Dr. Manuel Camelo A.C., Glaxo, Gliatech, Hastings Center, Janssen, Juste Pharmaceutical Spain, McNeil, Medice Pharmaceuticals (Germany), Merck, MGH Psychiatry Academy, MMC Pediatric, NARSAD, NIDA, New River, NICHD, NIMH, Novartis, Noven, Neurosearch, Organon, Otsuka, Pfizer, Pharmacia, Phase V Communications, Physicians Academy, The Prechter Foundation, Quantia Communications, Reed Exhibitions, Shionogi Pharma Inc, Shire, the Spanish Child Psychiatry Association, The Stanley Foundation, UCB Pharma, Inc., Veritas, and Wyeth. N.W.C., C.Z., and M.U. have no conflict of interest relevant to this article to disclose. Funding Information: This work was supported by philanthropic funding from the Demarest Lloyd, Jr. Foundation. The funding source had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the article.

PY - 2017/10

Y1 - 2017/10

UR - http://www.scopus.com/inward/record.url?scp=85031694896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031694896&partnerID=8YFLogxK

U2 - 10.1089/cap.2017.0080

DO - 10.1089/cap.2017.0080

M3 - Letter

C2 - 28661708

AN - SCOPUS:85031694896

SN - 1044-5463

VL - 27

SP - 755

EP - 756

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

IS - 8

ER -